YorkaPig-HF-RBM20 Swine by is a Other medication manufactured, distributed, or labeled by Recombinetics, Inc.. Drug facts, warnings, and ingredients follow.
Identity: Transcription activator-like effector nuclease (TALEN) edit and homology dependent repair in Yorkshire breed porcine fetal fibroblasts to introduce a C>A base substitution at base pair 121,244,982 that generates a BglII restriction enzyme site used to genotype progeny from gene edited founders, a CG>TC base substitution at base pairs 121,244,988-121,244,989 that creates a coding sequence change from arginine to serine at amino acid 638 of the swine RBM20 protein, and a synonymous AG>TC base substitution at base pairs 121,244,991-121,244,992.
Conditions of Use: This model animal and any products derived from it are for biomedical research purposes only and not for use in humans. This is an investigational animal. Edible products of investigational animals are not to be used for food unless authorization has been granted by the U.S. Food and Drug Administration or by the U.S. Department of Agriculture.
WARNINGS & PRECAUTIONS:
Caution. This intentionally genetically altered animal and any products derived from it are for biomedical
research purposes only and are not for use in humans or as human or animal food.
YorkaPig-HF-RBM20 animals are not for resale. No reproduction, distribution, transportation, or other third
party transfer is allowed by the purchaser unless specifically agreed to in writing by Recombinetics, Inc.
YorkaPig-HF-RBM20 animals, or any materials derived from the YorkaPig-HF-RBM20 animals, are not intended
to enter the human or animal food supply.
YorkaPig-HF-RBM20 animals shall be euthanized in accordance with all applicable regulatory or industry
standards, and all animal remains must be disposed of by incineration. Purchaser must maintain detailed
records accounting for the location of all YorkaPig-HF-RBM20 animals, and all materials derived from the
YorkaPig-HF-RBM20 animals, from the time the animals are delivered to Purchaser through disposition by
incineration. Final disposition notification must be made to Recombinetics, Inc.
rbm20 bglii restriction fragment length polymorphism (rflp) positive for one or two copies of rbm20-r636s not applicable
|Labeler - Recombinetics, Inc. (829874523)|
|Registrant - Recombinetics, Inc. (829874523)|